Chardan Capital reiterated their buy rating on shares of Caladrius Biosciences (NASDAQ:CLBS) in a report released on Sunday morning, AnalystRatings.com reports. They currently have a $6.00 target price on the biotechnology company’s stock.

“Maintaining Perform rating after better-than-expected 1Q results, but expect continued heavy investment and uncertainty around Homes. IMT EBITDA was 76%/71% above Opco/Street, significantly higher on two non-recurring accounting adjustments, and management raised the low-end of FY guidance for PA and IMT, suggesting re-acceleration. However, Offers bought 898 homes and sold 414, resulting in an increase of homes in inventory from 509 in 4Q to 993 in 1Q. This suggests some homes were older than 90 days and this was evidenced by inventory doubling over the quarter from $163M in 4Q to $325M. We remain on the sidelines on uncertainty around terminal unit economics and management pushing its five-year targets to longer” than originally assumed.”,” the firm’s analyst commented.

CLBS has been the topic of several other reports. Zacks Investment Research downgraded shares of Caladrius Biosciences from a buy rating to a hold rating in a research note on Friday, February 1st. Dawson James restated a buy rating on shares of Caladrius Biosciences in a research note on Wednesday, February 27th. HC Wainwright restated a buy rating and issued a $18.50 price target on shares of Caladrius Biosciences in a research note on Thursday, January 24th. Finally, ValuEngine downgraded shares of Caladrius Biosciences from a buy rating to a hold rating in a research note on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $9.25.

NASDAQ:CLBS opened at $3.09 on Friday. Caladrius Biosciences has a one year low of $2.77 and a one year high of $11.65.

Caladrius Biosciences (NASDAQ:CLBS) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.05). Analysts forecast that Caladrius Biosciences will post -1.64 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the stock. Morgan Stanley grew its stake in shares of Caladrius Biosciences by 218.6% in the first quarter. Morgan Stanley now owns 6,996 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 4,800 shares in the last quarter. Vanguard Group Inc grew its stake in shares of Caladrius Biosciences by 2.9% in the third quarter. Vanguard Group Inc now owns 202,568 shares of the biotechnology company’s stock valued at $1,196,000 after acquiring an additional 5,700 shares in the last quarter. Wesbanco Bank Inc. bought a new stake in Caladrius Biosciences during the first quarter worth about $36,000. Finally, Renaissance Technologies LLC lifted its position in Caladrius Biosciences by 6.9% during the first quarter. Renaissance Technologies LLC now owns 315,348 shares of the biotechnology company’s stock worth $1,142,000 after purchasing an additional 20,253 shares during the period. Institutional investors and hedge funds own 7.10% of the company’s stock.

About Caladrius Biosciences

Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Recommended Story: Economic Reports

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.